Real-World Patterns of Utilization of Lenalidomide-based Triplet Regimens in FIrst RElapsed Multiple Myeloma Patients: Evidence From Medical Record Review

Fondazione IRCCS Policlinico San Matteo di Pavia100 enrolled

Overview

To compare progression-free survival (PFS) in patients with first-relapse multiple myeloma treated with Rd-based "triplets" (Daratumumab + Rd (DaraRd) vs Carfilzomib + Rd (KRd) vs. Elotuzumab + Rd (EloRd) vs. Ixazomib + Rd (IxaRd))

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Multiple Mieloma First Relpase Rd-base Triplet

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with multiple myeloma (MM) at first relapse treated starting in January 2017 with RD-based triplets in accordance with current clinical practice * Age ≥18 years * Written informed consent signed by the patient Exclusion Criteria: * the patient's refusal to participate

Locations (1)

Fondazione IRCCS Policlinico San Matteo

Pavia, Italy

Outcomes

Primary Outcomes

Comparison of progression-free survival (PFS) in patients with multiple myeloma at first relapse treated with Rd-based "triplet" regimens (Daratumumab + Rd (DaraRd) vs Carfilzomib + Rd (KRd) vs Elotuzumab + Rd (EloRd) vs Ixazomib + Rd (IxaRd))

Time frame: The study is expected to run for 24 months starting with the enrollment of the first patient in November 2020

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.